Literature DB >> 21037210

Is the EQ-5D fit for purpose in mental health?

John Brazier.   

Abstract

The EQ-5D is a widely used questionnaire for calculating quality-adjusted life-years (QALYs) for assessing cost-effectiveness in healthcare. It reflects the impact of common mental health conditions such as mild to moderate depression but seems to be more problematic for use in people with psychotic and severe and complex non-psychotic disorders.

Entities:  

Mesh：

Year:  2010        PMID： 21037210     DOI： 10.1192/bjp.bp.110.082453

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN： 0007-1250            Impact factor:   9.319


  51 in total

1.  Tailored care for somatoform vertigo/dizziness: study protocol for a randomised controlled trial evaluating integrative group psychotherapy.

Authors:  Claas Lahmann; P Henningsen; M Dieterich; K Radziej; G Schmid
Journal:  J Neurol       Date:  2015-05-23       Impact factor: 4.849

Review 2.  Assessment of the construct validity and responsiveness of preference-based quality of life measures in people with Parkinson's: a systematic review.

Authors:  Yiqiao Xin; Emma McIntosh
Journal:  Qual Life Res       Date:  2016-10-24       Impact factor: 4.147

3.  Does the EQ-5D capture the effects of physical and mental health status on life satisfaction among older people? A path analysis approach.

Authors:  Eithne Sexton; Kathleen Bennett; Tom Fahey; Caitriona Cahir
Journal:  Qual Life Res       Date:  2016-11-19       Impact factor: 4.147

4.  Community treatment orders and social outcomes for patients with psychosis: a 48-month follow-up study.

Authors:  Francis Vergunst; Jorun Rugkåsa; Constantinos Koshiaris; Judit Simon; Tom Burns
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2017-09-12       Impact factor: 4.328

5.  The impact of depression on health-related quality of life and wellbeing: identifying important dimensions and assessing their inclusion in multi-attribute utility instruments.

Authors:  Lidia Engel; Gang Chen; Jeffrey Richardson; Cathrine Mihalopoulos
Journal:  Qual Life Res       Date:  2018-07-13       Impact factor: 4.147

6.  Usefulness of EQ-5D for evaluation of health-related quality of life in young adults with first-episode psychosis.

Authors:  J Stochl; T Croudace; J Perez; M Birchwood; H Lester; M Marshall; T Amos; V Sharma; D Fowler; P B Jones
Journal:  Qual Life Res       Date:  2012-06-17       Impact factor: 4.147

7.  Cost-Effectiveness Evaluations of Psychological Therapies for Schizophrenia and Bipolar Disorder: A Systematic Review.

Authors:  Gemma Elizabeth Shields; Deborah Buck; Jamie Elvidge; Karen Petra Hayhurst; Linda Mary Davies
Journal:  Int J Technol Assess Health Care       Date:  2019-07-22       Impact factor: 2.188

8.  interRAI Subjective Quality of Life Scale for Mental Health and Addiction Settings: A Self-Reported Measure Developed From a Multi-National Study.

Authors:  Hao Luo; Alice Hirdes; Jyrki Heikkilä; Kathleen De Cuyper; Chantal Van Audenhove; Margaret Saari; John P Hirdes
Journal:  Front Psychiatry       Date:  2021-07-09       Impact factor: 4.157

9.  Exploring the use of health and wellbeing measures during pregnancy and the first year following birth in women living with pre-existing long-term conditions: qualitative interviews with women and healthcare professionals.

Authors:  Laura Kelly; Jennifer J Kurinczuk; Oliver Rivero-Arias; Ray Fitzpatrick; Elizabeth Gibbons; Fiona Alderdice
Journal:  BMC Health Serv Res       Date:  2021-06-24       Impact factor: 2.655

10.  A multi-site single blind clinical study to compare the effects of prolonged exposure, eye movement desensitization and reprocessing and waiting list on patients with a current diagnosis of psychosis and co morbid post traumatic stress disorder: study protocol for the randomized controlled trial Treating Trauma in Psychosis.

Authors:  Paul A J M de Bont; David P G van den Berg; Berber M van der Vleugel; Carlijn de Roos; Cornelis L Mulder; Eni S Becker; Ad de Jongh; Mark van der Gaag; Agnes van Minnen
Journal:  Trials       Date:  2013-05-23       Impact factor: 2.279
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.